Process for the manufacture of cellulose sulfate with improved characteristics

Details for Australian Patent Application No. 2006221969 (hide)

Owner Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V. Ziel Biopharma Ltd.

Inventors Fischer, Steffen; Wagenknecht, Wolfgang; Hauser, Oliver; Hettrich, Kay

Agent Shelston IP

Pub. Number AU-B-2006221969

PCT Pub. Number WO2006/095021

Priority 10 2005 011 367.2 11.03.05 DE

Filing date 10 March 2006

Wipo publication date 14 September 2006

Acceptance publication date 26 May 2011

International Classifications

C08B 7/00 (2006.01) Preparation of cellulose esters of both organic and inorganic acids

Event Publications

18 October 2007 PCT application entered the National Phase

  PCT publication WO2006/095021 Priority application(s): WO2006/095021

6 November 2008 Assignment before Grant

  Austrianova Biotechnology GmbH; Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V. The application has been assigned to Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.; Ziel Biopharma Ltd.

26 May 2011 Application Accepted

  Published as AU-B-2006221969

22 September 2011 Standard Patent Sealed

4 October 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006221980-Cosmetic and dermatological preparations containing transparent surfacecoated titanium dioxide particles

2006221964-Anti-proliferative combination therapy comprising satraplatin or JM118 and a taxane